nodes	percent_of_prediction	percent_of_DWPC	metapath
Tolvaptan—Vismodegib—Sorafenib—kidney cancer	0.448	1	CrCrCtD
Tolvaptan—ABCB1—kidney cancer	0.147	1	CbGaD
Tolvaptan—ABCB1—Temsirolimus—kidney cancer	0.0318	0.134	CbGbCtD
Tolvaptan—CYP3A4—Everolimus—kidney cancer	0.0282	0.119	CbGbCtD
Tolvaptan—AVPR2—collecting duct of renal tubule—kidney cancer	0.0273	0.455	CbGeAlD
Tolvaptan—CYP3A4—Temsirolimus—kidney cancer	0.0191	0.0802	CbGbCtD
Tolvaptan—ABCB1—Pazopanib—kidney cancer	0.0167	0.0704	CbGbCtD
Tolvaptan—ABCB1—Dactinomycin—kidney cancer	0.0153	0.0643	CbGbCtD
Tolvaptan—AVPR2—nephron—kidney cancer	0.0122	0.203	CbGeAlD
Tolvaptan—ABCB1—Gemcitabine—kidney cancer	0.0121	0.0509	CbGbCtD
Tolvaptan—ABCB1—Erlotinib—kidney cancer	0.0119	0.0502	CbGbCtD
Tolvaptan—ABCB1—Paclitaxel—kidney cancer	0.0109	0.046	CbGbCtD
Tolvaptan—CYP3A4—Pazopanib—kidney cancer	0.01	0.0422	CbGbCtD
Tolvaptan—AVPR2—urine—kidney cancer	0.00975	0.163	CbGeAlD
Tolvaptan—ABCB1—Sorafenib—kidney cancer	0.0097	0.0408	CbGbCtD
Tolvaptan—ABCB1—Vinblastine—kidney cancer	0.00958	0.0403	CbGbCtD
Tolvaptan—ABCB1—Vincristine—kidney cancer	0.00942	0.0396	CbGbCtD
Tolvaptan—ABCB1—Sunitinib—kidney cancer	0.00786	0.0331	CbGbCtD
Tolvaptan—CYP3A4—Erlotinib—kidney cancer	0.00715	0.0301	CbGbCtD
Tolvaptan—CYP3A4—Paclitaxel—kidney cancer	0.00655	0.0275	CbGbCtD
Tolvaptan—ABCB1—Doxorubicin—kidney cancer	0.00589	0.0248	CbGbCtD
Tolvaptan—CYP3A4—Sorafenib—kidney cancer	0.00581	0.0245	CbGbCtD
Tolvaptan—CYP3A4—Vinblastine—kidney cancer	0.00574	0.0241	CbGbCtD
Tolvaptan—CYP3A4—Vincristine—kidney cancer	0.00564	0.0237	CbGbCtD
Tolvaptan—CYP3A4—Sunitinib—kidney cancer	0.00471	0.0198	CbGbCtD
Tolvaptan—CYP3A4—Doxorubicin—kidney cancer	0.00353	0.0148	CbGbCtD
Tolvaptan—AVPR2—nephron tubule—kidney cancer	0.00263	0.0437	CbGeAlD
Tolvaptan—AVPR2—renal system—kidney cancer	0.00239	0.0398	CbGeAlD
Tolvaptan—AVPR2—kidney—kidney cancer	0.00231	0.0384	CbGeAlD
Tolvaptan—CYP3A4—urine—kidney cancer	0.00148	0.0247	CbGeAlD
Tolvaptan—Zafirlukast—PTGS1—kidney cancer	0.000581	0.708	CrCbGaD
Tolvaptan—CYP3A4—renal system—kidney cancer	0.000363	0.00605	CbGeAlD
Tolvaptan—CYP3A4—kidney—kidney cancer	0.000351	0.00585	CbGeAlD
Tolvaptan—ABCB1—nephron tubule—kidney cancer	0.000283	0.00471	CbGeAlD
Tolvaptan—ABCB1—renal system—kidney cancer	0.000257	0.00429	CbGeAlD
Tolvaptan—ABCB1—kidney—kidney cancer	0.000249	0.00414	CbGeAlD
Tolvaptan—ABCB1—cortex of kidney—kidney cancer	0.000242	0.00403	CbGeAlD
Tolvaptan—Vismodegib—ABCB1—kidney cancer	0.000239	0.292	CrCbGaD
Tolvaptan—ABCB1—gonad—kidney cancer	0.000231	0.00384	CbGeAlD
Tolvaptan—Angiopathy—Vincristine—kidney cancer	0.000145	0.00141	CcSEcCtD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—kidney cancer	0.000145	0.0014	CcSEcCtD
Tolvaptan—Ill-defined disorder—Dactinomycin—kidney cancer	0.000145	0.0014	CcSEcCtD
Tolvaptan—Hyperuricaemia—Doxorubicin—kidney cancer	0.000144	0.0014	CcSEcCtD
Tolvaptan—Mediastinal disorder—Vincristine—kidney cancer	0.000144	0.0014	CcSEcCtD
Tolvaptan—Pruritus—Pazopanib—kidney cancer	0.000144	0.0014	CcSEcCtD
Tolvaptan—Hyperglycaemia—Paclitaxel—kidney cancer	0.000143	0.00139	CcSEcCtD
Tolvaptan—Dizziness—Temsirolimus—kidney cancer	0.000143	0.00139	CcSEcCtD
Tolvaptan—Dry mouth—Sorafenib—kidney cancer	0.000142	0.00138	CcSEcCtD
Tolvaptan—Blood bilirubin increased—Doxorubicin—kidney cancer	0.000141	0.00137	CcSEcCtD
Tolvaptan—Blood creatinine increased—Capecitabine—kidney cancer	0.000141	0.00137	CcSEcCtD
Tolvaptan—Cardiac disorder—Gemcitabine—kidney cancer	0.000141	0.00137	CcSEcCtD
Tolvaptan—Malaise—Dactinomycin—kidney cancer	0.00014	0.00136	CcSEcCtD
Tolvaptan—Decreased appetite—Vinblastine—kidney cancer	0.00014	0.00136	CcSEcCtD
Tolvaptan—Dehydration—Capecitabine—kidney cancer	0.00014	0.00136	CcSEcCtD
Tolvaptan—Decreased appetite—Everolimus—kidney cancer	0.00014	0.00136	CcSEcCtD
Tolvaptan—Anaphylactic shock—Sorafenib—kidney cancer	0.00014	0.00135	CcSEcCtD
Tolvaptan—Diarrhoea—Pazopanib—kidney cancer	0.000139	0.00135	CcSEcCtD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Sunitinib—kidney cancer	0.000139	0.00135	CcSEcCtD
Tolvaptan—Renal failure—Paclitaxel—kidney cancer	0.000139	0.00135	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Everolimus—kidney cancer	0.000139	0.00135	CcSEcCtD
Tolvaptan—Constipation—Vinblastine—kidney cancer	0.000138	0.00134	CcSEcCtD
Tolvaptan—Angiopathy—Gemcitabine—kidney cancer	0.000138	0.00133	CcSEcCtD
Tolvaptan—Orthostatic hypotension—Capecitabine—kidney cancer	0.000138	0.00133	CcSEcCtD
Tolvaptan—Constipation—Everolimus—kidney cancer	0.000137	0.00133	CcSEcCtD
Tolvaptan—Shock—Sorafenib—kidney cancer	0.000137	0.00133	CcSEcCtD
Tolvaptan—Dry mouth—Sunitinib—kidney cancer	0.000137	0.00133	CcSEcCtD
Tolvaptan—Immune system disorder—Gemcitabine—kidney cancer	0.000137	0.00133	CcSEcCtD
Tolvaptan—Nervous system disorder—Sorafenib—kidney cancer	0.000137	0.00133	CcSEcCtD
Tolvaptan—Mediastinal disorder—Gemcitabine—kidney cancer	0.000137	0.00133	CcSEcCtD
Tolvaptan—Blood uric acid increased—Doxorubicin—kidney cancer	0.000136	0.00132	CcSEcCtD
Tolvaptan—Breast disorder—Capecitabine—kidney cancer	0.000136	0.00132	CcSEcCtD
Tolvaptan—Aspartate aminotransferase increased—Capecitabine—kidney cancer	0.000136	0.00132	CcSEcCtD
Tolvaptan—Skin disorder—Sorafenib—kidney cancer	0.000136	0.00132	CcSEcCtD
Tolvaptan—Headache—Temsirolimus—kidney cancer	0.000135	0.00131	CcSEcCtD
Tolvaptan—Decreased appetite—Erlotinib—kidney cancer	0.000135	0.00131	CcSEcCtD
Tolvaptan—Dizziness—Pazopanib—kidney cancer	0.000135	0.00131	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Erlotinib—kidney cancer	0.000134	0.0013	CcSEcCtD
Tolvaptan—Pulmonary embolism—Doxorubicin—kidney cancer	0.000134	0.0013	CcSEcCtD
Tolvaptan—Anorexia—Sorafenib—kidney cancer	0.000133	0.00129	CcSEcCtD
Tolvaptan—Feeling abnormal—Vinblastine—kidney cancer	0.000133	0.00129	CcSEcCtD
Tolvaptan—Alanine aminotransferase increased—Capecitabine—kidney cancer	0.000133	0.00129	CcSEcCtD
Tolvaptan—Constipation—Erlotinib—kidney cancer	0.000133	0.00129	CcSEcCtD
Tolvaptan—Feeling abnormal—Everolimus—kidney cancer	0.000132	0.00129	CcSEcCtD
Tolvaptan—Shock—Sunitinib—kidney cancer	0.000132	0.00128	CcSEcCtD
Tolvaptan—Nervous system disorder—Sunitinib—kidney cancer	0.000132	0.00128	CcSEcCtD
Tolvaptan—Hyperkalaemia—Doxorubicin—kidney cancer	0.000131	0.00127	CcSEcCtD
Tolvaptan—Discomfort—Dactinomycin—kidney cancer	0.000131	0.00127	CcSEcCtD
Tolvaptan—Skin disorder—Sunitinib—kidney cancer	0.00013	0.00127	CcSEcCtD
Tolvaptan—Nausea—Temsirolimus—kidney cancer	0.000128	0.00125	CcSEcCtD
Tolvaptan—Anorexia—Sunitinib—kidney cancer	0.000128	0.00124	CcSEcCtD
Tolvaptan—Headache—Pazopanib—kidney cancer	0.000128	0.00124	CcSEcCtD
Tolvaptan—Body temperature increased—Everolimus—kidney cancer	0.000127	0.00123	CcSEcCtD
Tolvaptan—Urinary tract disorder—Paclitaxel—kidney cancer	0.000125	0.00122	CcSEcCtD
Tolvaptan—Connective tissue disorder—Paclitaxel—kidney cancer	0.000125	0.00121	CcSEcCtD
Tolvaptan—Urethral disorder—Paclitaxel—kidney cancer	0.000124	0.00121	CcSEcCtD
Tolvaptan—Body temperature increased—Erlotinib—kidney cancer	0.000123	0.00119	CcSEcCtD
Tolvaptan—Ill-defined disorder—Gemcitabine—kidney cancer	0.000122	0.00119	CcSEcCtD
Tolvaptan—Decreased appetite—Sorafenib—kidney cancer	0.000121	0.00118	CcSEcCtD
Tolvaptan—Anorexia—Dactinomycin—kidney cancer	0.000121	0.00118	CcSEcCtD
Tolvaptan—Nausea—Pazopanib—kidney cancer	0.000121	0.00117	CcSEcCtD
Tolvaptan—Ecchymosis—Doxorubicin—kidney cancer	0.000121	0.00117	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Sorafenib—kidney cancer	0.00012	0.00117	CcSEcCtD
Tolvaptan—Constipation—Sorafenib—kidney cancer	0.000119	0.00116	CcSEcCtD
Tolvaptan—Malaise—Gemcitabine—kidney cancer	0.000119	0.00116	CcSEcCtD
Tolvaptan—Hypersensitivity—Vinblastine—kidney cancer	0.000119	0.00115	CcSEcCtD
Tolvaptan—Hypersensitivity—Everolimus—kidney cancer	0.000118	0.00115	CcSEcCtD
Tolvaptan—Cardiac disorder—Paclitaxel—kidney cancer	0.000118	0.00114	CcSEcCtD
Tolvaptan—Hyperglycaemia—Capecitabine—kidney cancer	0.000117	0.00114	CcSEcCtD
Tolvaptan—Decreased appetite—Sunitinib—kidney cancer	0.000117	0.00113	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Sunitinib—kidney cancer	0.000116	0.00112	CcSEcCtD
Tolvaptan—Asthenia—Vinblastine—kidney cancer	0.000116	0.00112	CcSEcCtD
Tolvaptan—Asthenia—Everolimus—kidney cancer	0.000115	0.00112	CcSEcCtD
Tolvaptan—Angiopathy—Paclitaxel—kidney cancer	0.000115	0.00112	CcSEcCtD
Tolvaptan—Constipation—Sunitinib—kidney cancer	0.000115	0.00111	CcSEcCtD
Tolvaptan—Immune system disorder—Paclitaxel—kidney cancer	0.000115	0.00111	CcSEcCtD
Tolvaptan—Mediastinal disorder—Paclitaxel—kidney cancer	0.000114	0.00111	CcSEcCtD
Tolvaptan—Renal failure—Capecitabine—kidney cancer	0.000114	0.00111	CcSEcCtD
Tolvaptan—Pruritus—Everolimus—kidney cancer	0.000114	0.0011	CcSEcCtD
Tolvaptan—Anaphylactic shock—Vincristine—kidney cancer	0.000114	0.0011	CcSEcCtD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—kidney cancer	0.000112	0.00108	CcSEcCtD
Tolvaptan—Nervous system disorder—Vincristine—kidney cancer	0.000111	0.00108	CcSEcCtD
Tolvaptan—Asthenia—Erlotinib—kidney cancer	0.000111	0.00108	CcSEcCtD
Tolvaptan—Discomfort—Gemcitabine—kidney cancer	0.000111	0.00108	CcSEcCtD
Tolvaptan—Malnutrition—Paclitaxel—kidney cancer	0.000111	0.00107	CcSEcCtD
Tolvaptan—Decreased appetite—Dactinomycin—kidney cancer	0.000111	0.00107	CcSEcCtD
Tolvaptan—Diarrhoea—Vinblastine—kidney cancer	0.00011	0.00107	CcSEcCtD
Tolvaptan—Body temperature increased—Sorafenib—kidney cancer	0.00011	0.00107	CcSEcCtD
Tolvaptan—Diarrhoea—Everolimus—kidney cancer	0.00011	0.00107	CcSEcCtD
Tolvaptan—Pruritus—Erlotinib—kidney cancer	0.00011	0.00106	CcSEcCtD
Tolvaptan—Anorexia—Vincristine—kidney cancer	0.000108	0.00105	CcSEcCtD
Tolvaptan—Dysgeusia—Paclitaxel—kidney cancer	0.000108	0.00105	CcSEcCtD
Tolvaptan—Anaphylactic shock—Gemcitabine—kidney cancer	0.000108	0.00105	CcSEcCtD
Tolvaptan—Dizziness—Vinblastine—kidney cancer	0.000107	0.00104	CcSEcCtD
Tolvaptan—Dizziness—Everolimus—kidney cancer	0.000106	0.00103	CcSEcCtD
Tolvaptan—Body temperature increased—Sunitinib—kidney cancer	0.000106	0.00103	CcSEcCtD
Tolvaptan—Diarrhoea—Erlotinib—kidney cancer	0.000106	0.00103	CcSEcCtD
Tolvaptan—Nervous system disorder—Gemcitabine—kidney cancer	0.000106	0.00103	CcSEcCtD
Tolvaptan—Feeling abnormal—Dactinomycin—kidney cancer	0.000105	0.00102	CcSEcCtD
Tolvaptan—Skin disorder—Gemcitabine—kidney cancer	0.000105	0.00102	CcSEcCtD
Tolvaptan—Urinary tract disorder—Capecitabine—kidney cancer	0.000103	0.000998	CcSEcCtD
Tolvaptan—Hypersensitivity—Sorafenib—kidney cancer	0.000103	0.000998	CcSEcCtD
Tolvaptan—Anorexia—Gemcitabine—kidney cancer	0.000103	0.000996	CcSEcCtD
Tolvaptan—Dizziness—Erlotinib—kidney cancer	0.000103	0.000995	CcSEcCtD
Tolvaptan—Ill-defined disorder—Paclitaxel—kidney cancer	0.000103	0.000995	CcSEcCtD
Tolvaptan—Connective tissue disorder—Capecitabine—kidney cancer	0.000102	0.000993	CcSEcCtD
Tolvaptan—Urethral disorder—Capecitabine—kidney cancer	0.000102	0.000991	CcSEcCtD
Tolvaptan—Renal impairment—Doxorubicin—kidney cancer	0.000102	0.00099	CcSEcCtD
Tolvaptan—Headache—Vinblastine—kidney cancer	0.000101	0.000981	CcSEcCtD
Tolvaptan—Headache—Everolimus—kidney cancer	0.000101	0.000977	CcSEcCtD
Tolvaptan—Body temperature increased—Dactinomycin—kidney cancer	0.0001	0.000975	CcSEcCtD
Tolvaptan—Asthenia—Sorafenib—kidney cancer	0.0001	0.000971	CcSEcCtD
Tolvaptan—Malaise—Paclitaxel—kidney cancer	9.97e-05	0.000967	CcSEcCtD
Tolvaptan—Hypoglycaemia—Doxorubicin—kidney cancer	9.95e-05	0.000965	CcSEcCtD
Tolvaptan—Syncope—Paclitaxel—kidney cancer	9.91e-05	0.000962	CcSEcCtD
Tolvaptan—Cerebrovascular accident—Doxorubicin—kidney cancer	9.91e-05	0.000961	CcSEcCtD
Tolvaptan—Hypersensitivity—Sunitinib—kidney cancer	9.89e-05	0.00096	CcSEcCtD
Tolvaptan—Decreased appetite—Vincristine—kidney cancer	9.87e-05	0.000958	CcSEcCtD
Tolvaptan—Pruritus—Sorafenib—kidney cancer	9.87e-05	0.000958	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Vincristine—kidney cancer	9.81e-05	0.000951	CcSEcCtD
Tolvaptan—Hyponatraemia—Doxorubicin—kidney cancer	9.75e-05	0.000946	CcSEcCtD
Tolvaptan—Headache—Erlotinib—kidney cancer	9.72e-05	0.000943	CcSEcCtD
Tolvaptan—Loss of consciousness—Paclitaxel—kidney cancer	9.71e-05	0.000943	CcSEcCtD
Tolvaptan—Constipation—Vincristine—kidney cancer	9.71e-05	0.000942	CcSEcCtD
Tolvaptan—Gastrointestinal haemorrhage—Doxorubicin—kidney cancer	9.71e-05	0.000942	CcSEcCtD
Tolvaptan—Cardiac disorder—Capecitabine—kidney cancer	9.67e-05	0.000938	CcSEcCtD
Tolvaptan—Asthenia—Sunitinib—kidney cancer	9.63e-05	0.000935	CcSEcCtD
Tolvaptan—Nausea—Vinblastine—kidney cancer	9.59e-05	0.00093	CcSEcCtD
Tolvaptan—Nausea—Everolimus—kidney cancer	9.55e-05	0.000926	CcSEcCtD
Tolvaptan—Diarrhoea—Sorafenib—kidney cancer	9.55e-05	0.000926	CcSEcCtD
Tolvaptan—Pruritus—Sunitinib—kidney cancer	9.5e-05	0.000922	CcSEcCtD
Tolvaptan—Angiopathy—Capecitabine—kidney cancer	9.45e-05	0.000917	CcSEcCtD
Tolvaptan—Immune system disorder—Capecitabine—kidney cancer	9.41e-05	0.000913	CcSEcCtD
Tolvaptan—Mediastinal disorder—Capecitabine—kidney cancer	9.39e-05	0.000911	CcSEcCtD
Tolvaptan—Decreased appetite—Gemcitabine—kidney cancer	9.37e-05	0.000909	CcSEcCtD
Tolvaptan—Hypersensitivity—Dactinomycin—kidney cancer	9.37e-05	0.000909	CcSEcCtD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	9.35e-05	0.000907	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Gemcitabine—kidney cancer	9.3e-05	0.000903	CcSEcCtD
Tolvaptan—Discomfort—Paclitaxel—kidney cancer	9.3e-05	0.000902	CcSEcCtD
Tolvaptan—Dizziness—Sorafenib—kidney cancer	9.23e-05	0.000895	CcSEcCtD
Tolvaptan—Constipation—Gemcitabine—kidney cancer	9.21e-05	0.000894	CcSEcCtD
Tolvaptan—Nausea—Erlotinib—kidney cancer	9.21e-05	0.000894	CcSEcCtD
Tolvaptan—Dry mouth—Paclitaxel—kidney cancer	9.2e-05	0.000893	CcSEcCtD
Tolvaptan—Diarrhoea—Sunitinib—kidney cancer	9.19e-05	0.000891	CcSEcCtD
Tolvaptan—Asthenia—Dactinomycin—kidney cancer	9.12e-05	0.000885	CcSEcCtD
Tolvaptan—Blood creatinine increased—Doxorubicin—kidney cancer	9.1e-05	0.000882	CcSEcCtD
Tolvaptan—Malnutrition—Capecitabine—kidney cancer	9.07e-05	0.00088	CcSEcCtD
Tolvaptan—Dehydration—Doxorubicin—kidney cancer	9.03e-05	0.000876	CcSEcCtD
Tolvaptan—Anaphylactic shock—Paclitaxel—kidney cancer	9.02e-05	0.000875	CcSEcCtD
Tolvaptan—Body temperature increased—Vincristine—kidney cancer	8.98e-05	0.000871	CcSEcCtD
Tolvaptan—Dysgeusia—Capecitabine—kidney cancer	8.88e-05	0.000862	CcSEcCtD
Tolvaptan—Dizziness—Sunitinib—kidney cancer	8.88e-05	0.000862	CcSEcCtD
Tolvaptan—Feeling abnormal—Gemcitabine—kidney cancer	8.88e-05	0.000861	CcSEcCtD
Tolvaptan—Shock—Paclitaxel—kidney cancer	8.87e-05	0.000861	CcSEcCtD
Tolvaptan—Orthostatic hypotension—Doxorubicin—kidney cancer	8.87e-05	0.00086	CcSEcCtD
Tolvaptan—Nervous system disorder—Paclitaxel—kidney cancer	8.85e-05	0.000858	CcSEcCtD
Tolvaptan—Breast disorder—Doxorubicin—kidney cancer	8.77e-05	0.000851	CcSEcCtD
Tolvaptan—Skin disorder—Paclitaxel—kidney cancer	8.76e-05	0.00085	CcSEcCtD
Tolvaptan—Aspartate aminotransferase increased—Doxorubicin—kidney cancer	8.74e-05	0.000848	CcSEcCtD
Tolvaptan—Headache—Sorafenib—kidney cancer	8.74e-05	0.000848	CcSEcCtD
Tolvaptan—Diarrhoea—Dactinomycin—kidney cancer	8.7e-05	0.000844	CcSEcCtD
Tolvaptan—Anorexia—Paclitaxel—kidney cancer	8.6e-05	0.000834	CcSEcCtD
Tolvaptan—Alanine aminotransferase increased—Doxorubicin—kidney cancer	8.56e-05	0.000831	CcSEcCtD
Tolvaptan—Body temperature increased—Gemcitabine—kidney cancer	8.52e-05	0.000826	CcSEcCtD
Tolvaptan—Ill-defined disorder—Capecitabine—kidney cancer	8.42e-05	0.000817	CcSEcCtD
Tolvaptan—Headache—Sunitinib—kidney cancer	8.41e-05	0.000816	CcSEcCtD
Tolvaptan—Hypersensitivity—Vincristine—kidney cancer	8.37e-05	0.000812	CcSEcCtD
Tolvaptan—Nausea—Sorafenib—kidney cancer	8.29e-05	0.000804	CcSEcCtD
Tolvaptan—Malaise—Capecitabine—kidney cancer	8.18e-05	0.000794	CcSEcCtD
Tolvaptan—Asthenia—Vincristine—kidney cancer	8.15e-05	0.000791	CcSEcCtD
Tolvaptan—Syncope—Capecitabine—kidney cancer	8.13e-05	0.000789	CcSEcCtD
Tolvaptan—Nausea—Sunitinib—kidney cancer	7.98e-05	0.000774	CcSEcCtD
Tolvaptan—Loss of consciousness—Capecitabine—kidney cancer	7.97e-05	0.000774	CcSEcCtD
Tolvaptan—Decreased appetite—Paclitaxel—kidney cancer	7.84e-05	0.000761	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Paclitaxel—kidney cancer	7.79e-05	0.000756	CcSEcCtD
Tolvaptan—Diarrhoea—Vincristine—kidney cancer	7.77e-05	0.000754	CcSEcCtD
Tolvaptan—Pollakiuria—Doxorubicin—kidney cancer	7.75e-05	0.000752	CcSEcCtD
Tolvaptan—Asthenia—Gemcitabine—kidney cancer	7.73e-05	0.00075	CcSEcCtD
Tolvaptan—Constipation—Paclitaxel—kidney cancer	7.71e-05	0.000748	CcSEcCtD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	7.67e-05	0.000744	CcSEcCtD
Tolvaptan—Discomfort—Capecitabine—kidney cancer	7.63e-05	0.00074	CcSEcCtD
Tolvaptan—Pruritus—Gemcitabine—kidney cancer	7.62e-05	0.00074	CcSEcCtD
Tolvaptan—Hyperglycaemia—Doxorubicin—kidney cancer	7.57e-05	0.000734	CcSEcCtD
Tolvaptan—Dry mouth—Capecitabine—kidney cancer	7.55e-05	0.000733	CcSEcCtD
Tolvaptan—Nausea—Dactinomycin—kidney cancer	7.55e-05	0.000733	CcSEcCtD
Tolvaptan—Dizziness—Vincristine—kidney cancer	7.51e-05	0.000729	CcSEcCtD
Tolvaptan—Feeling abnormal—Paclitaxel—kidney cancer	7.43e-05	0.000721	CcSEcCtD
Tolvaptan—Diarrhoea—Gemcitabine—kidney cancer	7.37e-05	0.000715	CcSEcCtD
Tolvaptan—Renal failure—Doxorubicin—kidney cancer	7.35e-05	0.000714	CcSEcCtD
Tolvaptan—Shock—Capecitabine—kidney cancer	7.28e-05	0.000707	CcSEcCtD
Tolvaptan—Nervous system disorder—Capecitabine—kidney cancer	7.26e-05	0.000704	CcSEcCtD
Tolvaptan—Skin disorder—Capecitabine—kidney cancer	7.19e-05	0.000698	CcSEcCtD
Tolvaptan—Body temperature increased—Paclitaxel—kidney cancer	7.13e-05	0.000692	CcSEcCtD
Tolvaptan—Headache—Vincristine—kidney cancer	7.12e-05	0.00069	CcSEcCtD
Tolvaptan—Anorexia—Capecitabine—kidney cancer	7.06e-05	0.000685	CcSEcCtD
Tolvaptan—Headache—Gemcitabine—kidney cancer	6.75e-05	0.000655	CcSEcCtD
Tolvaptan—Nausea—Vincristine—kidney cancer	6.75e-05	0.000655	CcSEcCtD
Tolvaptan—Hypersensitivity—Paclitaxel—kidney cancer	6.65e-05	0.000645	CcSEcCtD
Tolvaptan—Urinary tract disorder—Doxorubicin—kidney cancer	6.63e-05	0.000644	CcSEcCtD
Tolvaptan—Connective tissue disorder—Doxorubicin—kidney cancer	6.6e-05	0.00064	CcSEcCtD
Tolvaptan—Urethral disorder—Doxorubicin—kidney cancer	6.58e-05	0.000639	CcSEcCtD
Tolvaptan—Asthenia—Paclitaxel—kidney cancer	6.47e-05	0.000628	CcSEcCtD
Tolvaptan—Decreased appetite—Capecitabine—kidney cancer	6.44e-05	0.000624	CcSEcCtD
Tolvaptan—Nausea—Gemcitabine—kidney cancer	6.4e-05	0.000621	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Capecitabine—kidney cancer	6.39e-05	0.00062	CcSEcCtD
Tolvaptan—Pruritus—Paclitaxel—kidney cancer	6.38e-05	0.000619	CcSEcCtD
Tolvaptan—Constipation—Capecitabine—kidney cancer	6.33e-05	0.000614	CcSEcCtD
Tolvaptan—Cardiac disorder—Doxorubicin—kidney cancer	6.23e-05	0.000605	CcSEcCtD
Tolvaptan—Diarrhoea—Paclitaxel—kidney cancer	6.17e-05	0.000599	CcSEcCtD
Tolvaptan—Feeling abnormal—Capecitabine—kidney cancer	6.1e-05	0.000592	CcSEcCtD
Tolvaptan—Angiopathy—Doxorubicin—kidney cancer	6.09e-05	0.000591	CcSEcCtD
Tolvaptan—Immune system disorder—Doxorubicin—kidney cancer	6.07e-05	0.000589	CcSEcCtD
Tolvaptan—Mediastinal disorder—Doxorubicin—kidney cancer	6.05e-05	0.000587	CcSEcCtD
Tolvaptan—Dizziness—Paclitaxel—kidney cancer	5.97e-05	0.000579	CcSEcCtD
Tolvaptan—Body temperature increased—Capecitabine—kidney cancer	5.85e-05	0.000568	CcSEcCtD
Tolvaptan—Malnutrition—Doxorubicin—kidney cancer	5.85e-05	0.000567	CcSEcCtD
Tolvaptan—Dysgeusia—Doxorubicin—kidney cancer	5.73e-05	0.000556	CcSEcCtD
Tolvaptan—Headache—Paclitaxel—kidney cancer	5.65e-05	0.000548	CcSEcCtD
Tolvaptan—Hypersensitivity—Capecitabine—kidney cancer	5.45e-05	0.000529	CcSEcCtD
Tolvaptan—Ill-defined disorder—Doxorubicin—kidney cancer	5.42e-05	0.000526	CcSEcCtD
Tolvaptan—Nausea—Paclitaxel—kidney cancer	5.36e-05	0.00052	CcSEcCtD
Tolvaptan—Asthenia—Capecitabine—kidney cancer	5.31e-05	0.000515	CcSEcCtD
Tolvaptan—Malaise—Doxorubicin—kidney cancer	5.27e-05	0.000512	CcSEcCtD
Tolvaptan—Syncope—Doxorubicin—kidney cancer	5.24e-05	0.000509	CcSEcCtD
Tolvaptan—Pruritus—Capecitabine—kidney cancer	5.24e-05	0.000508	CcSEcCtD
Tolvaptan—Loss of consciousness—Doxorubicin—kidney cancer	5.14e-05	0.000499	CcSEcCtD
Tolvaptan—Diarrhoea—Capecitabine—kidney cancer	5.07e-05	0.000491	CcSEcCtD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	4.94e-05	0.00048	CcSEcCtD
Tolvaptan—Discomfort—Doxorubicin—kidney cancer	4.92e-05	0.000477	CcSEcCtD
Tolvaptan—Dizziness—Capecitabine—kidney cancer	4.9e-05	0.000475	CcSEcCtD
Tolvaptan—Dry mouth—Doxorubicin—kidney cancer	4.87e-05	0.000472	CcSEcCtD
Tolvaptan—Anaphylactic shock—Doxorubicin—kidney cancer	4.77e-05	0.000463	CcSEcCtD
Tolvaptan—Shock—Doxorubicin—kidney cancer	4.69e-05	0.000456	CcSEcCtD
Tolvaptan—Nervous system disorder—Doxorubicin—kidney cancer	4.68e-05	0.000454	CcSEcCtD
Tolvaptan—Headache—Capecitabine—kidney cancer	4.64e-05	0.00045	CcSEcCtD
Tolvaptan—Skin disorder—Doxorubicin—kidney cancer	4.64e-05	0.00045	CcSEcCtD
Tolvaptan—Anorexia—Doxorubicin—kidney cancer	4.55e-05	0.000441	CcSEcCtD
Tolvaptan—Nausea—Capecitabine—kidney cancer	4.4e-05	0.000427	CcSEcCtD
Tolvaptan—Decreased appetite—Doxorubicin—kidney cancer	4.15e-05	0.000402	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Doxorubicin—kidney cancer	4.12e-05	0.0004	CcSEcCtD
Tolvaptan—Constipation—Doxorubicin—kidney cancer	4.08e-05	0.000396	CcSEcCtD
Tolvaptan—Feeling abnormal—Doxorubicin—kidney cancer	3.93e-05	0.000382	CcSEcCtD
Tolvaptan—Body temperature increased—Doxorubicin—kidney cancer	3.77e-05	0.000366	CcSEcCtD
Tolvaptan—Hypersensitivity—Doxorubicin—kidney cancer	3.52e-05	0.000341	CcSEcCtD
Tolvaptan—Asthenia—Doxorubicin—kidney cancer	3.42e-05	0.000332	CcSEcCtD
Tolvaptan—Pruritus—Doxorubicin—kidney cancer	3.38e-05	0.000328	CcSEcCtD
Tolvaptan—Diarrhoea—Doxorubicin—kidney cancer	3.26e-05	0.000317	CcSEcCtD
Tolvaptan—Dizziness—Doxorubicin—kidney cancer	3.16e-05	0.000306	CcSEcCtD
Tolvaptan—Headache—Doxorubicin—kidney cancer	2.99e-05	0.00029	CcSEcCtD
Tolvaptan—Nausea—Doxorubicin—kidney cancer	2.83e-05	0.000275	CcSEcCtD
Tolvaptan—AVPR2—GPCR downstream signaling—ITPR2—kidney cancer	1.53e-05	0.00457	CbGpPWpGaD
Tolvaptan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—kidney cancer	1.48e-05	0.00441	CbGpPWpGaD
Tolvaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—POMC—kidney cancer	1.47e-05	0.00439	CbGpPWpGaD
Tolvaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—POMC—kidney cancer	1.46e-05	0.00436	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—GPC3—kidney cancer	1.42e-05	0.00424	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—CER1—kidney cancer	1.42e-05	0.00424	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—GPC3—kidney cancer	1.41e-05	0.00421	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—CER1—kidney cancer	1.41e-05	0.00421	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—ITPR2—kidney cancer	1.4e-05	0.00418	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—ITPR2—kidney cancer	1.39e-05	0.00415	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR downstream signaling—ANXA1—kidney cancer	1.3e-05	0.00386	CbGpPWpGaD
Tolvaptan—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—kidney cancer	1.29e-05	0.00385	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—ANXA1—kidney cancer	1.29e-05	0.00383	CbGpPWpGaD
Tolvaptan—AVPR2—Transmembrane transport of small molecules—ABCB1—kidney cancer	1.26e-05	0.00375	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—SFRP2—kidney cancer	1.21e-05	0.0036	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—SFRP2—kidney cancer	1.2e-05	0.00358	CbGpPWpGaD
Tolvaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—kidney cancer	1.18e-05	0.00353	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—ANXA1—kidney cancer	1.18e-05	0.0035	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—ANXA1—kidney cancer	1.17e-05	0.00348	CbGpPWpGaD
Tolvaptan—ABCB1—HIF-1-alpha transcription factor network—HIF1A—kidney cancer	1.16e-05	0.00344	CbGpPWpGaD
Tolvaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—kidney cancer	1.13e-05	0.00336	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR ligand binding—POMC—kidney cancer	1.12e-05	0.00335	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—APAF1—kidney cancer	1.11e-05	0.00332	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—JUND—kidney cancer	1.11e-05	0.00332	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR ligand binding—POMC—kidney cancer	1.11e-05	0.00332	CbGpPWpGaD
Tolvaptan—AVPR1A—G alpha (q) signalling events—PIK3CA—kidney cancer	1.09e-05	0.00326	CbGpPWpGaD
Tolvaptan—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—kidney cancer	1.09e-05	0.00324	CbGpPWpGaD
Tolvaptan—CYP3A4—Tryptophan metabolism—CYP1A1—kidney cancer	1.07e-05	0.00318	CbGpPWpGaD
Tolvaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—kidney cancer	1.06e-05	0.00317	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—kidney cancer	1.06e-05	0.00315	CbGpPWpGaD
Tolvaptan—CYP3A4—Biological oxidations—ALDH1A1—kidney cancer	1.05e-05	0.00312	CbGpPWpGaD
Tolvaptan—ABCB1—Transmembrane transport of small molecules—RYR1—kidney cancer	1.04e-05	0.00309	CbGpPWpGaD
Tolvaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—kidney cancer	9.77e-06	0.00291	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—AKAP13—kidney cancer	9.75e-06	0.00291	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—CASP2—kidney cancer	9.75e-06	0.00291	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—AKAP13—kidney cancer	9.68e-06	0.00288	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—CASP2—kidney cancer	9.68e-06	0.00288	CbGpPWpGaD
Tolvaptan—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—kidney cancer	9.29e-06	0.00277	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—ACHE—kidney cancer	9.2e-06	0.00274	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—GRB7—kidney cancer	8.92e-06	0.00266	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—GRB7—kidney cancer	8.85e-06	0.00264	CbGpPWpGaD
Tolvaptan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—kidney cancer	8.64e-06	0.00257	CbGpPWpGaD
Tolvaptan—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—kidney cancer	8.52e-06	0.00254	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—ANXA1—kidney cancer	8.45e-06	0.00252	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—ITPR2—kidney cancer	8.29e-06	0.00247	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—ITPR2—kidney cancer	8.23e-06	0.00245	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—JUNB—kidney cancer	7.59e-06	0.00226	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—PAK1—kidney cancer	7.59e-06	0.00226	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—CTNNA1—kidney cancer	7.52e-06	0.00224	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—HSPB1—kidney cancer	7.47e-06	0.00223	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—EIF4EBP1—kidney cancer	7.47e-06	0.00223	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—CTNNA1—kidney cancer	7.46e-06	0.00222	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—EIF4EBP1—kidney cancer	7.42e-06	0.00221	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—HSPB1—kidney cancer	7.42e-06	0.00221	CbGpPWpGaD
Tolvaptan—AVPR2—Transmembrane transport of small molecules—RAF1—kidney cancer	7.11e-06	0.00212	CbGpPWpGaD
Tolvaptan—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—kidney cancer	7.11e-06	0.00212	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—EGR1—kidney cancer	7.1e-06	0.00211	CbGpPWpGaD
Tolvaptan—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—kidney cancer	7e-06	0.00209	CbGpPWpGaD
Tolvaptan—ABCB1—HIF-1-alpha transcription factor network—JUN—kidney cancer	6.97e-06	0.00208	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—PSMD7—kidney cancer	6.95e-06	0.00207	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—ANXA1—kidney cancer	6.95e-06	0.00207	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—TSC1—kidney cancer	6.95e-06	0.00207	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—PSMD7—kidney cancer	6.9e-06	0.00206	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—ANXA1—kidney cancer	6.9e-06	0.00206	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—TSC1—kidney cancer	6.9e-06	0.00206	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—FLT1—kidney cancer	6.73e-06	0.00201	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—FLT1—kidney cancer	6.68e-06	0.00199	CbGpPWpGaD
Tolvaptan—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—kidney cancer	6.44e-06	0.00192	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR downstream signaling—POMC—kidney cancer	6.35e-06	0.00189	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—POMC—kidney cancer	6.3e-06	0.00188	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—PAK1—kidney cancer	6.24e-06	0.00186	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—JUNB—kidney cancer	6.24e-06	0.00186	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—kidney cancer	6.23e-06	0.00186	CbGpPWpGaD
Tolvaptan—ABCB1—Allograft Rejection—IL2—kidney cancer	6.2e-06	0.00185	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—JUNB—kidney cancer	6.19e-06	0.00185	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—PAK1—kidney cancer	6.19e-06	0.00185	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN2B—kidney cancer	6.17e-06	0.00184	CbGpPWpGaD
Tolvaptan—CYP3A4—Biological oxidations—GSTT1—kidney cancer	6.16e-06	0.00184	CbGpPWpGaD
Tolvaptan—ABCB1—HIF-1-alpha transcription factor network—VEGFA—kidney cancer	6.09e-06	0.00181	CbGpPWpGaD
Tolvaptan—ABCB1—Transmembrane transport of small molecules—SLC5A3—kidney cancer	5.96e-06	0.00178	CbGpPWpGaD
Tolvaptan—ABCB1—Transmembrane transport of small molecules—ATP7B—kidney cancer	5.96e-06	0.00178	CbGpPWpGaD
Tolvaptan—ABCB1—Transmembrane transport of small molecules—ANXA2—kidney cancer	5.96e-06	0.00178	CbGpPWpGaD
Tolvaptan—CYP3A4—Biological oxidations—PTGS1—kidney cancer	5.77e-06	0.00172	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—POMC—kidney cancer	5.76e-06	0.00172	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—POMC—kidney cancer	5.72e-06	0.0017	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—ACY1—kidney cancer	5.31e-06	0.00158	CbGpPWpGaD
Tolvaptan—ABCB1—Allograft Rejection—VEGFA—kidney cancer	5.27e-06	0.00157	CbGpPWpGaD
Tolvaptan—CYP3A4—Phase 1 - Functionalization of compounds—POMC—kidney cancer	5.22e-06	0.00156	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—IGF2—kidney cancer	5.1e-06	0.00152	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—CDKN2B—kidney cancer	5.08e-06	0.00151	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—IGF2—kidney cancer	5.06e-06	0.00151	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—CDKN2B—kidney cancer	5.04e-06	0.0015	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—IGF1R—kidney cancer	4.93e-06	0.00147	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—IGF1R—kidney cancer	4.9e-06	0.00146	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—RAF1—kidney cancer	4.75e-06	0.00142	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—RAF1—kidney cancer	4.72e-06	0.00141	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR downstream signaling—IL2—kidney cancer	4.69e-06	0.0014	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—IL2—kidney cancer	4.66e-06	0.00139	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—PDHB—kidney cancer	4.52e-06	0.00135	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—APC—kidney cancer	4.35e-06	0.0013	CbGpPWpGaD
Tolvaptan—CYP3A4—Biological oxidations—GSTP1—kidney cancer	4.27e-06	0.00127	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—IL2—kidney cancer	4.26e-06	0.00127	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—CCBL1—kidney cancer	4.25e-06	0.00127	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—IL2—kidney cancer	4.23e-06	0.00126	CbGpPWpGaD
Tolvaptan—CYP3A4—Metapathway biotransformation—GSTP1—kidney cancer	4.21e-06	0.00126	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—HIF1A—kidney cancer	4.06e-06	0.00121	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—TSC2—kidney cancer	4.05e-06	0.00121	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—HIF1A—kidney cancer	4.03e-06	0.0012	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—TSC2—kidney cancer	4.02e-06	0.0012	CbGpPWpGaD
Tolvaptan—CYP3A4—Biological oxidations—GSTM1—kidney cancer	3.92e-06	0.00117	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—KDR—kidney cancer	3.88e-06	0.00116	CbGpPWpGaD
Tolvaptan—CYP3A4—Metapathway biotransformation—GSTM1—kidney cancer	3.87e-06	0.00115	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—KDR—kidney cancer	3.85e-06	0.00115	CbGpPWpGaD
Tolvaptan—CYP3A4—Biological oxidations—CYP1A1—kidney cancer	3.72e-06	0.00111	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—GLIPR1—kidney cancer	3.68e-06	0.0011	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—PPAT—kidney cancer	3.68e-06	0.0011	CbGpPWpGaD
Tolvaptan—CYP3A4—Metapathway biotransformation—CYP1A1—kidney cancer	3.67e-06	0.00109	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—KIT—kidney cancer	3.58e-06	0.00107	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—APC—kidney cancer	3.58e-06	0.00107	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—KIT—kidney cancer	3.55e-06	0.00106	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—APC—kidney cancer	3.55e-06	0.00106	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—MAPK3—kidney cancer	3.42e-06	0.00102	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—APRT—kidney cancer	3.42e-06	0.00102	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—FH—kidney cancer	3.42e-06	0.00102	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—kidney cancer	3.41e-06	0.00102	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—POMC—kidney cancer	3.4e-06	0.00101	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—MAPK3—kidney cancer	3.4e-06	0.00101	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—POMC—kidney cancer	3.38e-06	0.00101	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—kidney cancer	3.38e-06	0.00101	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—BRAF—kidney cancer	3.36e-06	0.001	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—BRAF—kidney cancer	3.34e-06	0.000994	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—kidney cancer	3.3e-06	0.000984	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—ACY1—kidney cancer	3.27e-06	0.000975	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—MAPK1—kidney cancer	3.26e-06	0.000971	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—MAPK1—kidney cancer	3.24e-06	0.000964	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—GPC3—kidney cancer	3.22e-06	0.000959	CbGpPWpGaD
Tolvaptan—ABCB1—Transmembrane transport of small molecules—SLC5A5—kidney cancer	3.14e-06	0.000936	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—CA2—kidney cancer	3.13e-06	0.000933	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—kidney cancer	3.13e-06	0.000932	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR downstream signaling—PIK3CA—kidney cancer	3.11e-06	0.000928	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—PIK3CA—kidney cancer	3.09e-06	0.000921	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—KRAS—kidney cancer	3.08e-06	0.000917	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—KRAS—kidney cancer	3.06e-06	0.000911	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—ALAD—kidney cancer	3.05e-06	0.000909	CbGpPWpGaD
Tolvaptan—ABCB1—Transmembrane transport of small molecules—SLC2A1—kidney cancer	3.03e-06	0.000904	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—kidney cancer	2.98e-06	0.000889	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—ST3GAL2—kidney cancer	2.98e-06	0.000887	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—kidney cancer	2.98e-06	0.000887	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—kidney cancer	2.95e-06	0.00088	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—ALDH1A1—kidney cancer	2.91e-06	0.000867	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—kidney cancer	2.88e-06	0.000858	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—PIK3CA—kidney cancer	2.83e-06	0.000843	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—PIK3CA—kidney cancer	2.81e-06	0.000837	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—RAF1—kidney cancer	2.81e-06	0.000836	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—RELA—kidney cancer	2.79e-06	0.000833	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—SLC5A3—kidney cancer	2.79e-06	0.000831	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—PGK1—kidney cancer	2.79e-06	0.000831	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—RAF1—kidney cancer	2.79e-06	0.00083	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—PDHB—kidney cancer	2.78e-06	0.000829	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—ERBB2—kidney cancer	2.78e-06	0.000827	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—RELA—kidney cancer	2.77e-06	0.000827	CbGpPWpGaD
Tolvaptan—CYP3A4—Biological oxidations—POMC—kidney cancer	2.77e-06	0.000827	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—ERBB2—kidney cancer	2.76e-06	0.000822	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—MTOR—kidney cancer	2.74e-06	0.000817	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—LDHB—kidney cancer	2.74e-06	0.000815	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—MTOR—kidney cancer	2.72e-06	0.000811	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—CCBL1—kidney cancer	2.62e-06	0.00078	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—kidney cancer	2.6e-06	0.000775	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—CDKN1B—kidney cancer	2.57e-06	0.000766	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—CDKN1B—kidney cancer	2.55e-06	0.000761	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—IL2—kidney cancer	2.52e-06	0.00075	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—IL2—kidney cancer	2.5e-06	0.000745	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—kidney cancer	2.46e-06	0.000733	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—CCND1—kidney cancer	2.45e-06	0.000731	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—JUN—kidney cancer	2.45e-06	0.00073	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—CCND1—kidney cancer	2.44e-06	0.000726	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—JUN—kidney cancer	2.43e-06	0.000724	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—CTNNB1—kidney cancer	2.43e-06	0.000724	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—CTNNB1—kidney cancer	2.41e-06	0.000719	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—kidney cancer	2.39e-06	0.000713	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—CA9—kidney cancer	2.37e-06	0.000707	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—PTEN—kidney cancer	2.37e-06	0.000706	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—PTEN—kidney cancer	2.35e-06	0.000701	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—kidney cancer	2.34e-06	0.000698	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—GLIPR1—kidney cancer	2.27e-06	0.000676	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—PPAT—kidney cancer	2.27e-06	0.000676	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—kidney cancer	2.21e-06	0.000659	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—VEGFA—kidney cancer	2.14e-06	0.000637	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—VEGFA—kidney cancer	2.12e-06	0.000633	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—FH—kidney cancer	2.11e-06	0.000628	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—APRT—kidney cancer	2.11e-06	0.000628	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—kidney cancer	2.03e-06	0.000605	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—MAPK3—kidney cancer	2.02e-06	0.000603	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—CRABP1—kidney cancer	2.02e-06	0.000601	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—MAPK3—kidney cancer	2.01e-06	0.000599	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—GPC3—kidney cancer	1.98e-06	0.000591	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—MYC—kidney cancer	1.97e-06	0.000586	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—kidney cancer	1.97e-06	0.000586	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—MYC—kidney cancer	1.95e-06	0.000582	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—CA2—kidney cancer	1.93e-06	0.000575	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—MAPK1—kidney cancer	1.92e-06	0.000574	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—MAPK1—kidney cancer	1.91e-06	0.00057	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—ALAD—kidney cancer	1.88e-06	0.00056	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—ITPR2—kidney cancer	1.88e-06	0.000559	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—ST3GAL2—kidney cancer	1.83e-06	0.000547	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—KRAS—kidney cancer	1.82e-06	0.000542	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—KRAS—kidney cancer	1.81e-06	0.000538	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—ALDH1A1—kidney cancer	1.79e-06	0.000534	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—SLC5A3—kidney cancer	1.72e-06	0.000512	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—PGK1—kidney cancer	1.72e-06	0.000512	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—GSTT1—kidney cancer	1.71e-06	0.00051	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—ACHE—kidney cancer	1.71e-06	0.00051	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—LDHB—kidney cancer	1.69e-06	0.000502	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—PIK3CA—kidney cancer	1.67e-06	0.000498	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—PIK3CA—kidney cancer	1.66e-06	0.000494	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—SCARB1—kidney cancer	1.62e-06	0.000482	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—TP53—kidney cancer	1.62e-06	0.000482	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—TP53—kidney cancer	1.6e-06	0.000478	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—PTGS1—kidney cancer	1.6e-06	0.000478	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—PSMD7—kidney cancer	1.57e-06	0.000468	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—BCHE—kidney cancer	1.49e-06	0.000444	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—SLC5A5—kidney cancer	1.47e-06	0.000439	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—CA9—kidney cancer	1.46e-06	0.000436	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—SLC2A1—kidney cancer	1.42e-06	0.000424	CbGpPWpGaD
Tolvaptan—ABCB1—Transmembrane transport of small molecules—RAF1—kidney cancer	1.36e-06	0.000404	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—CRABP1—kidney cancer	1.24e-06	0.00037	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—GSTP1—kidney cancer	1.19e-06	0.000353	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—ITPR2—kidney cancer	1.16e-06	0.000344	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—GSTM1—kidney cancer	1.09e-06	0.000325	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—GSTT1—kidney cancer	1.05e-06	0.000314	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—ACHE—kidney cancer	1.05e-06	0.000314	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—CYP1A1—kidney cancer	1.03e-06	0.000308	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—SCARB1—kidney cancer	9.97e-07	0.000297	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—PTGS1—kidney cancer	9.87e-07	0.000294	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—PSMD7—kidney cancer	9.68e-07	0.000289	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—BCHE—kidney cancer	9.18e-07	0.000274	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—SLC5A5—kidney cancer	9.07e-07	0.00027	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—SLC2A1—kidney cancer	8.76e-07	0.000261	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—POMC—kidney cancer	7.7e-07	0.000229	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—GSTP1—kidney cancer	7.3e-07	0.000218	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—ABCB1—kidney cancer	6.91e-07	0.000206	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—GSTM1—kidney cancer	6.71e-07	0.0002	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—CYP1A1—kidney cancer	6.36e-07	0.00019	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—PTGS2—kidney cancer	6.14e-07	0.000183	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—PTEN—kidney cancer	5.36e-07	0.00016	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—POMC—kidney cancer	4.74e-07	0.000141	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—PTGS2—kidney cancer	3.78e-07	0.000113	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—PIK3CA—kidney cancer	3.78e-07	0.000113	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—PTEN—kidney cancer	3.3e-07	9.83e-05	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—PIK3CA—kidney cancer	2.33e-07	6.94e-05	CbGpPWpGaD
